Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma.
Using a modified papain digestion cetylpyridinium salt precipitation method, glycosaminoglycans were isolated from 21 mesotheliomas, 34 primary lung carcinomas, 12 carcinomas of other sites, and 7 soft tissue sarcomas. Qualitatively, hyaluronic acid (HA) was present in 20 of 21 mesotheliomas, about half of the primary lung adenocarcinomas, and all of the soft tissue sarcomas. On the average, HA constituted 45% of the total glycosaminoglycans in the mesotheliomas and 28% of the total in the lung cancers. Quantitatively, mesotheliomas contained statistically greater amounts (mean value, 0.74 mg/g) of HA than primary lung adenocarcinomas (mean value, 0.08 mg/g), but were not statistically different from soft tissue sarcomas (mean value, 2.01 mg/g) or primary ovarian serous neoplasms (mean value, 0.92 mg/g). The study concludes that, contrary to previous reports, HA is neither the sole nor the predominant glycosaminoglycan in most mesotheliomas, but, given the proper clinical and histologic setting, the finding of sufficiently high levels (greater than 0.4 mg/g dry tissue extract) supports the diagnosis of mesothelioma when the alternative diagnosis is primary adenocarcinoma of lung.
D000230:Adenocarcinoma / Q000032:analysis; D002277:Carcinoma / Q000032:analysis; D002809:Chondroitin Sulfates / Q000032:analysis; D003871:Dermatan Sulfate / Q000032:analysis; D003937:Diagnosis, Differential; D004588:Electrophoresis, Cellulose Acetate; D005260:Female; D006025:Glycosaminoglycans / Q000032:analysis; D006497:Heparan Sulfate / Q000032:analysis; D006801:Humans; D006820:Hyaluronic Acid / Q000032:analysis*; D008175:Lung Neoplasms / Q000032:analysis; D008654:Mesothelioma / Q000032:analysis*; D010051:Ovarian Neoplasms / Q000032:analysis; D012509:Sarcoma / Q000032:analysis
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006025:Glycosaminoglycans; D006497:Heparan Sulfate; D006820:Hyaluronic Acid